1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > PharmaPoint: Neuropathic Pain - Current and Future Players

PharmaPoint: Neuropathic Pain - Current and Future Players

Summary

GlobalData has released its pharma report, “PharmaPoint: Neuropathic Pain - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Neuropathic Pain Market. The report identifies and analyses the key companies shaping and driving the global Neuropathic Pain market. The report provides insight into the competitive Neuropathic Pain landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

Scope

- Investigation of current and future market competition for Neuropathic Pain
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of the Neuropathic Pain sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving the Neuropathic Pain Market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global Neuropathic Pain market landscape? Identify, understand and capitalize

Table Of Contents

PharmaPoint: Neuropathic Pain - Current and Future Players
1 Table of Contents

2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
3 Market Outlook 12
3.1 Global Markets 12
3.1.1 Forecast 12
3.1.2 Drivers and Barriers - Global Issues 22
4 Current and Future Players 25
4.1 Overview 25
4.2 Trends in Corporate Strategy 27
4.3 Company Profiles 28
4.3.1 Pfizer 28
4.3.2 Eli Lilly 30
4.3.3 Grünenthal 32
4.3.4 Endo Health Solutions 35
4.3.5 Janssen Pharmaceuticals 36
4.3.6 Daiichi Sankyo 38
4.3.7 Convergence Pharmaceuticals 40
5 Appendix 42
5.1 Bibliography 42
5.2 Abbreviations 43
5.3 Methodology 44
5.4 Forecasting Methodology 44
5.4.1 Diagnosed PDN, PHN, and TN Patients 44
5.4.2 Percent Drug-Treated Patients 45
5.4.3 General Pricing Assumptions 45
5.4.4 Generic Erosion 45
5.5 Physicians and Specialists Included in This Study 46
5.6 About the Authors 48
5.6.1 Author 48
5.6.2 Global Head of Healthcare 49
5.7 About GlobalData 50
5.8 Disclaimer 50

1.1 List of Tables

Table 1: Global Sales Forecasts ($) for NP, 2012-2022 14
Table 2: Global Sales Forecasts ($) for PDN, 2012-2022 16
Table 3: Global Sales Forecasts ($) for PHN, 2012-2022 18
Table 4: Global Sales Forecasts ($) for TN, 2012-2022 20
Table 5: NP Market - Drivers and Barriers, 2012-2022 22
Table 6: Key Companies in the NP Market, 2014 26
Table 7: Pfizer's NP Portfolio Assessment, 2014 29
Table 8: Pfizer SWOT Analysis, 2013 30
Table 9: Eli Lilly's NP Portfolio Assessment, 2013 31
Table 10: Eli Lilly SWOT Analysis, 2013 32
Table 11: Grünenthal's NP Portfolio Assessment, 2013 34
Table 12: Grünenthal SWOT Analysis, 2013 34
Table 13: Endo Health Solutions' NP Portfolio Assessment, 2013 36
Table 14: Endo Health Solutions SWOT Analysis, 2013 36
Table 15: Janssen Pharmaceuticals' NP Portfolio Assessment, 2013 37
Table 16: Janssen Pharmaceuticals SWOT Analysis, 2013 38
Table 17: Daiichi Sankyo's NP Portfolio Assessment, 2013 39
Table 18: Daiichi Sankyo SWOT Analysis, 2013 40
Table 19: Convergence Pharmaceuticals' NP Portfolio Assessment, 2013 41
Table 20: Convergence Pharmaceuticals SWOT Analysis, 2013 41

1.2 List of Figures

Figure 1: Global Sales for NP by Region, 2012-2022 15
Figure 2: Global Sales for PDN by Drug Class, 2012-2022 17
Figure 3: Global Sales for PHN by Drug Class, 2012-2022 19
Figure 4: Global Sales for TN by Drug Class, 2012-2022 21
Figure 5: Company Portfolio Gap Analysis in NP, 2012-2022 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation

Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • August 2016
  • by GBI Research

Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation Summary Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

Global Markets for Diabetes Therapeutics and Diagnostics

Global Markets for Diabetes Therapeutics and Diagnostics

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Analyze the market for drugs used in the treatment of diabetes, it's technology and the industry as a whole - Identify important trends and provide sales forecasts by product categories ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.